TaiGen Biopharmaceuticals Holdings Limited reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was TWD 9.68 million compared to TWD 46.15 million a year ago. Net loss was TWD 33.19 million compared to TWD 43.65 million a year ago. Basic loss per share from continuing operations was TWD 0.05 compared to TWD 0.06 a year ago.